New Research Improves Cure Rates in Neuroblastoma Patients

Researchers from the Children’s Oncology Group (COG), the sole beneficiary of CureSearch fundraising, have demonstrated that a new experimental immunotherapy treatment using the chimeric monoclonal antibody, that targets a specific carbohydrate/lipid molecule which is present on the surface of neuroblastoma tumor cells and cytokines resulted in a 20% improvement in cure rates compared to the standard treatment used in the past.



Read the full article here